BIO-TECHNE Corp Financial and Nonfinancial Liabilities, Fair Value Disclosure
BIO-TECHNE Corp (TECH) had Financial and Nonfinancial Liabilities, Fair Value Disclosure of $20.51 million as of 2020-09-30, per its 10-Q filed 2020-11-09.
Discontinued › Notes › Fair Value, Net Asset (Liability)
us-gaap:LiabilitiesFairValueDisclosure · last filed 2020-11-09
- 2020-09-30: Financial and Nonfinancial Liabilities, Fair Value Disclosure $20.51M.
- 2020-06-30: Financial and Nonfinancial Liabilities, Fair Value Disclosure $23.47M.
- 2020-03-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $26.57M.
- 2019-12-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $23.83M.
| Period end | Financial and Nonfinancial Liabilities, Fair Value Disclosure |
|---|---|
| 2020-09-30 | $20.51M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $23.47M 10-Q · filed 2020-11-09 |
| 2020-03-31 | $26.57M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $23.83M 10-Q · filed 2020-02-06 |
| 2019-09-30 | $26.42M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $25.06M 10-K · filed 2020-08-26 |
| 2019-03-31 | $13.16M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $11.13M 10-Q · filed 2019-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |